Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-229 vs AD-2291 PK and Safety Study
NCT07385248Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of rebamipide in gastritis (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum concentration of drug in plasma and Area under the plasma concentration-time curve during dosing interval. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
rebamipide
03
Conditions
gastritis
Beyond the preview
Go deeper on NCT07385248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385248.